Habib Hamidi, PhD, MPH

DeepHeme, a high-performance, generalizable deep ensemble for bone marrow morphometry and hematologic diagnosis | Science Translational Medicine science.org/doi/10.1126/sc…

Grateful that our lead author publication "Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade" got published in the Journal Cancer Cell. @Cancer_Cell cell.com/cancer-cell/ab…

Online Now: Engineering cancer’s end: An interdisciplinary approach to confront the complexities of cancer dlvr.it/T7yqXS

Ah yes, the sweet sounds of Fox News hypocrisy

Super excited that our lead author paper got accepted into @Cancer_Cell

"Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC  ncbi.nlm.nih.gov/pmc/articles/P…

Our study: Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial aacrjournals.org/clincancerres/…

TRACERx is an interesting approach

Grateful to be part of this effort. Our work on tumor antigens got published today in the journal Translational Oncology. sciencedirect.com/science/articl…

It's like a jungle sometimes it makes me wonder How I keep from going under

@theMMRF Transcriptomic data from patients' NNMM and RRMM reveal potential mechanisms of tumor progression and immune evasion.

MMRF Transcriptomic data from patients' NNMM and RRMM reveal potential mechanisms of tumor progression and immune evasion. doi.org/10.3389/fonc.2… @theMMRF @FrontOncology

Our work (when I was at UMich) got published in AJKD. Congratulations to the team especially @Sean_Eddy_A2 @LauraMarianiMD Jeffrey B Hodgin and Laura Barisoni

Very grateful to represent our #atezolizumab #myeloma team @neoselma @HabibHamidPhD @ElieWassner presenting correlative data and Similarity Fusion Network analysis of high dimensional immune profiling #IMW2021 @genentech @IcahnMountSinai @theMMRF #mmsm

Get those shots, folks.

Clinical activity and biomarker analysis in the COMBI-i trial evaluating PD-1, BRAF and MEK inhibition in patients with advanced #melanoma demonstrate high response rates and uncover molecular correlates of long-term efficacy. nature.com/articles/s4159… #MelanomaAwarenessMonth

A panel at the @AACR annual meeting focused on vaccine hesitancy—in surveys, 32% of Americans expressed hesitancy in receiving a COVID-19 vaccine. #COVIDnCancer #AACR21 cancerletter.com/covid-19-cance…

Check out MUSLIM COMMUNITY ASSOCIATION causes.benevity.org/causes/840-382…

➡ Rationale and design of the Kidney Precision Medicine Project kidney-international.org/article/S0085-… @deboerih @azeloglu @XPOTASN @KPMProject

Our work identifying novel clinically actionable molecular patient subtype of RCC derived from integrated multi-omics evaluation of 823 tumors from RCC patients that are associated with differential clinical outcomes to angio blockade alone or with a checkpoint inhibitor.